VOLITIONRX: Armistice Capital reports 4.99% stake
VOLITIONRX LTD filing an amendment to a Schedule 13G reporting beneficial ownership of 6,449,635 common shares, representing 4.99% of the class.
Rhea-AI Filing Summary
VOLITIONRX LTD filing an amendment to a Schedule 13G reporting beneficial ownership of 6,449,635 common shares, representing 4.99% of the class. The filing attributes that position to Armistice Capital, LLC as investment manager of Armistice Capital Master Fund Ltd., with shared voting and dispositive power over those 6,449,635 shares. The statement is a joint filing that also names Steven Boyd and is signed on 02/17/2026.
Positive
- None.
Negative
- None.
Insights
Armistice Capital reports a passive sub-5% stake with shared control.
The amendment lists 6,449,635 shares beneficially owned, equal to 4.99% of common stock as reported. The filing states shared voting and shared dispositive power over those shares, reflecting investment-manager control on behalf of the Master Fund.
Holder decisions will determine any future disclosures or Form 13D triggers; timing and any trading plans are not stated in the provided excerpt.
Amendment clarifies beneficial ownership and joint-filing attribution under Rule 13d-1(k).
The filing explains that Armistice Capital is investment manager to the Master Fund and that Mr. Boyd may be deemed to beneficially own the securities due to his role. The Master Fund disclaims direct beneficial ownership based on its contractual inability to vote or dispose.
The signature block shows the amendment dated 02/17/2026; no statements about plans to buy or sell are included in the excerpt.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Armistice Capital report in VOLITIONRX (VNRX)?
Who is listed as the reporting persons on the Schedule 13G/A for VNRX?
When was the Schedule 13G/A amendment signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.